Journal of Andrology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Meistrich, M. L.
Right arrow Articles by Kangasniemi, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Meistrich, M. L.
Right arrow Articles by Kangasniemi, M.

Journal of Andrology, Vol 16, Issue 4 334-341, Copyright © 1995 by The American Society of Andrology


JOURNAL ARTICLE

Hormonal protection from cyclophosphamide-induced inactivation of rat stem spermatogonia

M. L. Meistrich, N. Parchuri, G. Wilson, B. Kurdoglu and M. Kangasniemi
Department of Experimental Radiotherapy, University of Texas M. D. Anderson Cancer Center, Houston, USA.

Studies of protection of testicular function from cyclophosphamide with hormonal pretreatment have been limited by the lack of a convenient model for cyclophosphamide-induced inactivation of stem spermatogonia. In the rat, the mortality from cyclophosphamide had prevented the administration of sufficient dosages to produce detectible damage to stem spermatogonia. To overcome this problem, we used bone marrow transplantation and sodium 2-mercaptoethanesulfonate (Mesna) treatment to raise the lethal dose for 50% of the animals (LD50) for cyclophosphamide from 275 to > 400 mg/kg body weight. In addition we used irradiation, 2 weeks prior to injection of cyclophosphamide, to greatly enhance the measured toxicity of cyclophosphamide towards stem spermatogonia. Whereas sperm counts at 9 weeks after a 300 mg/kg cyclophosphamide dose were reduced by only a factor of 1.6 without prior irradiation, they were reduced by a factor of 60 when 2.5 Gy of irradiation had been given. Dramatic protection against this toxicity was produced by hormone treatment with a gonadotropin-releasing hormone (GnRH) antagonist (Nal-Glu) and an antiandrogen (flutamide) following the radiation but prior to cyclophosphamide. This hormone treatment did not modify the stem cell toxicity of the radiation and it therefore must be protecting stem cells against cyclophosphamide-induced damage. Because GnRH antagonist-antiandrogen treatment can protect stem spermatogonial survival and/or function in the rat from cyclophosphamide-induced damage, if the same principles are applicable in human, hormonal pretreatment should be useful for preventing the prolonged azoospermia caused by chemotherapy with cyclophosphamide-containing protocols.


This article has been cited by other articles:


Home page
EndocrinologyHome page
G. Shetty, C. C. Y. Weng, K. L. Porter, Z. Zhang, P. Pakarinen, T. R. Kumar, and M. L. Meistrich
Spermatogonial Differentiation in Juvenile Spermatogonial Depletion (jsd) Mice with Androgen Receptor or Follicle-Stimulating Hormone Mutations
Endocrinology, July 1, 2006; 147(7): 3563 - 3570.
[Abstract] [Full Text] [PDF]


Home page
J ANIM SCIHome page
J. M. Oatley, A. Tibary, D. M. de Avila, J. E. Wheaton, D. J. McLean, and J. J. Reeves
Changes in spermatogenesis and endocrine function in the ram testis due to irradiation and active immunization against luteinizing hormone-releasing hormone
J Anim Sci, March 1, 2005; 83(3): 604 - 612.
[Abstract] [Full Text] [PDF]


Home page
Biol. Reprod.Home page
S. A. Hild, B. J. Attardi, and J. R. Reel
The Ability of a Gonadotropin-Releasing Hormone Antagonist, Acyline, to Prevent Irreversible Infertility Induced by the Indenopyridine, CDB-4022, in Adult Male Rats: The Role of Testosterone
Biol Reprod, July 1, 2004; 71(1): 348 - 358.
[Abstract] [Full Text] [PDF]


Home page
Biol. Reprod.Home page
A. Tohda, K. Matsumiya, Y. Tadokoro, K. Yomogida, Y. Miyagawa, K. Dohmae, A. Okuyama, and Y. Nishimune
Testosterone Suppresses Spermatogenesis in Juvenile Spermatogonial Depletion (jsd ) Mice
Biol Reprod, August 1, 2001; 65(2): 532 - 537.
[Abstract] [Full Text] [PDF]


Home page
Biol. Reprod.Home page
S. Ann Hild, M. L. Meistrich, R. P. Blye, and J. R. Reel
Lupron Depot Prevention of Antispermatogenic/Antifertility Activity of the Indenopyridine, CDB-4022, in the Rat
Biol Reprod, July 1, 2001; 65(1): 165 - 172.
[Abstract] [Full Text] [PDF]


Home page
Biol. Reprod.Home page
H. A. Schoenfeld, S. J. Hall, and K. Boekelheide
Continuously Proliferative Stem Germ Cells Partially Repopulate the Aged, Atrophic Rat Testis after Gonadotropin-Releasing Hormone Agonist Therapy
Biol Reprod, April 1, 2001; 64(4): 1273 - 1282.
[Abstract] [Full Text]


Home page
Rheumatology (Oxford)Home page
D. Jayne
Evidence-based treatment of systemic vasculitis
Rheumatology, June 1, 2000; 39(6): 585 - 595.
[Full Text] [PDF]


Home page
EndocrinologyHome page
K. T. Blanchard, J. Lee, and K. Boekelheide
Leuprolide, a Gonadotropin-Releasing Hormone Agonist, Reestablishes Spermatogenesis After 2,5-Hexanedione-Induced Irreversible Testicular Injury in the Rat, Resulting in Normalized Stem Cell Factor Expression
Endocrinology, January 1, 1998; 139(1): 236 - 244.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 by The American Society of Andrology.